Amgen Inc.
FG21 MUTANTS AND USES THEREOF
Last updated:
Abstract:
The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
Status:
Application
Type:
Utility
Filling date:
24 Jun 2021
Issue date:
14 Oct 2021